Graft failure is a serious complication of allogeneic BMT and occurs in 1-20% of allografted patients depending mainly upon the relationship of the patient and donor, the Allograft recipients are often unwell with significant organ dysfunction by the time delayed or failed extent of HLA identity, the underlying disease, and manipulation (usually T cell depletion) of the infused engraftment is diagnosed. We attempted to identify factors associated with graft failure, or death due to infeccells.
Patients and methods

Pancytopenia as a result of myeloablative chemoradiother-
The database of the Leukaemia Unit of the Royal Marsden apy is universal after allogeneic bone marrow transplanHospital contains prospectively collected comprehensive tation (BMT). Consequently, infections and hemorrhage are data on over 1600 patients with hematologic malignancies among the most important causes of death after BMT. treated in the unit since 1978. An important component of Increasing duration of pancytopenia is associated with an the database is the death section. Detailed information on increasing probability of complications such as serious the mode of death, disease status at death, and principal infections and bleeding. There is no universally accepted and contributory causes of death is entered into the database definition of delayed engraftment or prolonged pancytoby one of the senior attending physicians on the basis of penia after BMT, with no length of pancytopenia being all the clinical, laboratory, and autopsy data available. definitely safe. criteria (n = 712) were included: marrow as the source of largest uniform subgroup (n = 544), the analyses were repeated for this subgroup. The variables included in the hematopoietic support and first transplant procedure. Patients allografted after having relapsed following an autoCox analysis were the same as above except for the exclusion of 'donor' and 'prophylactic growth graft were excluded, as were second allografts. Syngeneic transplants were excluded.
factor administration' variables, and change in GVHD prophylaxis covariates (cyclosporine vs cyclosporinemethotrexate).
Definition of events
Two types of events were studied: death and death/second Donor marrow infusion. Death specified death primarily due to hemorrhage, infection or graft failure within 3 months of BMT but Marrow was harvested from the iliac crests of HLA-identprior to relapse (n = 52). Death/second infusion included ical sibling donors under general anesthesia on the day of death as specified above (n = 52) or a second infusion of transplantation. The target cell number for the harvest was allogeneic or autologous marrow as rescue for primary fail-2 × 10 8 nucleated cells per kg recipient body weight. The ure or delay of engraftment within 2 months of the first marrow was usually not depleted of T cells, and was infusion (n = 47; total n = 99). The 52 patients in the death infused into the patient essentially unmanipulated except as category also included a number of patients who received required for donor-recipient ABO blood group incompatisecond marrow infusions, whereas the 47 additional bility. 21 The murine anti-CD52 monoclonal antibodies patients who received top-up marrow represent those who Campath-1G or Campath-1M (kindly provided by Drs G either survived the first 3 months or, if they died within 3 Hale and H Waldmann, Cambridge, UK), were used to months, did not do so primarily because of infection, deplete the donor marrow of T cells in most cases, 22 while hemorrhage or graft failure.
a few patients received marrow depleted of T cells with the Importantly, inclusion of patients dying primarily of the anti-T-cell antibody UCHT1 or corticosteroids. specified complications ensured the exclusion of patients dying of these complications secondary to acute graftversus-host disease (GVHD) because the latter were classiGraft-versus-host disease prophylaxis fied as dying primarily of GVHD.
17
Before the intravenous formulation of cyclosporine became available, the drug was administered intramuscularly at the Statistical analysis dose of 25 mg/kg from day −1 for 5 days, and then orally at the dose of 12.5 mg/kg. After the intravenous formuSerial blood counts obtained by automated counters on the lation of cyclosporine became available, the drug was selected patients were analyzed to see if the leukocyte count administered intravenously at the dose of 3 mg/kg from day on days 2-22 after BMT (the day of marrow infusion was −1 until oral intake was resumed. The drug was then given designated as day 0) was predictive of death or orally at the dose of 12.5 mg/kg. Patients receiving a short death/second infusion. For each of these post-transplant course of methotrexate in addition to cyclosporine received days, patients were grouped on the basis of the leukocyte 15 mg/m 2 of the drug on day 1, and 10 mg/m 2 on days 3 counts (10 9 /l) in three ways (р0.1 vs Ͼ0.1, р0.2 vs Ͼ0.2, and 6, or on days 3, 6 and 11. and р0.3 vs Ͼ0.3), and the probabilities of death and Acute GVHD was usually diagnosed and graded on death/second infusion calculated using the method of the basis of clinical findings, and was treated with Kaplan and Meier. 18 The log-rank test was used to compare conventional-(2 mg/kg) or high-(10-20 mg/kg) dose the differences. 19 Each leukocyte count value was analyzed corticosteroids. in isolation, and no account was taken of the phenomenon of a fall in the counts after begining of the recovery (ie leukocytes of 0.2 × 10 9 /l on day 14 but 0.1 × 10 9 /l on day Growth factors 15).
The following factors were also analyzed in uni-and Myeloid growth factors were administered to selected groups of patients. Twenty patients received GM-CSF multivariate fashion 20 to see their effect on the probability of death or death/second infusion: age (р35 years vs Ͼ35 (molgramostim) between October 1988 and February 1990 in a double-blind, randomized, placebo-controlled years), sex, diagnosis (acute leukemia vs other), conditioning regimen (TBI-containing vs chemotherapy only), donor fashion. 23 Both G-CSF and GM-CSF came into common use only from 1993 onwards. Most unrelated and mismatch (HLA-identical sibling vs other), GVHD prophylaxis (T cell depletion vs no T cell depletion and cyclosporine alone transplant recipients from 1993 onwards received GM-CSF (molgramostim) or G-CF (filgrastim or lenograstim) provs no T cell depletion and cyclosporine-methotrexate), cell dose (Ͻ2.5 × 10 8 /kg vs у2.5 × 10 8 /kg), prophylactic phylatically from day 0 onwards. Recipients of matched sibling marrow received growth factors prophylactically if administration of a growth factor within 2 weeks of BMT (yes vs no; starting growth factors after 2 weeks due to the they were perceived to be high-risk (advanced age, previous history of severe infections, etc). clinical situation was classified as 'no'), and the leukocyte count on day 16 after BMT (р0.2 × 10 9 /l vs Ͼ0.2).
Any patient who was not on prophylactic growth factors was eligible for growth factor administration if the clinical Since patients receiving non-T cell-depleted marrow from HLA-identical siblings without any prophylactic situation was thought to be critical (usually uncontrolled infection). Patients not attaining an absolute neutrophil growth factor administration post-transplant constituted the 351 count of 0.1 × 10 9 /l by day 21 were started on G-CSF or unspecified/unidentified infection (n = 10), bacterial infection (n = 9), and fungal infection (n = 1), and the leukocyte GM-CSF, if they were not on it already.
count at the time of death was 0-18.9 (median 0.4) × 10 9 /l. The leukocyte count at the time of death/second infusion Graft failure was 0-18.9 (median 0.2) × 10 9 /l. Primary graft failure was defined as an absolute neutrophil count of Ͻ0.1 × 10 9 /l on day 21. 8 The usual course of The effect of the leukocyte counts action in this situation, in addition to starting growth factors, was a second infusion of cells from the same donor 2   Tables 2 and 3 show the effect of the serial leukocyte or an infusion of cryopreserved autologous cells. 16 The time counts on the probability of death and death/second varied depending upon the clinical condition of the patient, infusion, respectively. It is not surprising to note that the and the availability of the donor (especially unrelated leukocyte counts on days 2-10 do not affect the specified donors).
outcomes significantly. However, from day 12 onwards, the lower leukocyte count for each of the three comparisons on each day is significantly associated with an increased risk Supportive care
of death and death/second infusion. All patients were treated in protective isolation in rooms with positive-pressure ventilation. Blood products transMultivariate analysis fused were not screened for cytomegalovirus (CMV) antibody prior to 1985. After that CMV-seronegative patients
The choice of the day 16 count (р0.2/Ͼ0.2) for the multiwith CMV-seronegative donors received screened, CMVvariate analysis was to an extent arbitrary, and was based negative blood products. Fever during the neutropenic upon the fact that the number of patients at risk (р0.2, phase was treated with broad-spectrum antibodies and n = 114) was 20% of the total population (Tables 2 and 3 ), amphotericin as necessary. Antibiotic prophylaxis and therand therefore was not considered too large to introduce a apy varied in accordance with prevalent practices and putative therapeutic intervention. research programs. All research protocols were approved Tables 4 and 5 show that a leukocyte count of less than by the local institutional review board, and all patients and or equal to 0.2 × 10 9 /l on day 16 was the strongest factor donors gave informed consent.
predicting subsequent death or death/second infusion (Figures 1 and 2) . Additionally, mismatch and unrelated donor transplants were associated with a higher risk of both Results death and death/second infusion. In the overall group, female sex and an infused cell dose of Ͻ2.5 × 10 8 /kg also Patient characteristics are shown in Table 1 . Fifty-two influenced death but their effect and significance were patients fulfilled the definition of death, and 99 the defilower than the other factors. The day 16 leukocyte count nition of death/second infusion. The causes of death in the was the strongest factor amongst non-T cell-depleted, death group were graft failure (n = 17), bleeding (n = 15), HLA-identical sibling transplant recipients as well (Tables 4 and 5 ). The results of the multivariate analysis were similar after substitution of the day 16 leukocyte hemorrhage, or graft failure compared to those with higher leukocyte counts and those allografted from HLA-identical The numerator is the number of events and the denominator the total number of patients on the specified day. The 2 values were calculated from logrank tests. *Not statistically significant.
2 values of у3.85 are significant (P р 0.05).
Table 3
The relationship between the total leukocyte count and death/second infusion (as defined in the text) The numerator is the number of events and the denominator the total number of patients on the specified day. The 2 values were calculated from logrank tests. *Not statistically significant.
siblings. Additionally, patients receiving T cell-depleted mortality, we do not have any data concerning whether earlier intervention actually does make any difference to the marrow are at risk of primary failure of engraftment.
The finding that transplants from alternative donors are outcome. Indeed, it would be very difficult to design a prospective, controlled trial which could prove or disprove the riskier is not surprising. The increased risk of graft failure with T cell depletion has also been noted before. 4, 24, 25 Simiutility of early intervention. Routine administration of cytokines after allogeneic larly, the correlation between low leukocyte counts and complications is also to be expected although this has not BMT to all patients is expensive and probably unnecessary. 26 While it usually results in faster myeloid recovery, been specifically remarked upon. However, the main purpose of this exercise was to see if leukocyte counts relano prospective study has shown a beneficial impact on survival. In fact, growth factor administration has been found tively early after BMT could be used to identify patients at risk. We believe we have succeeded in showing this.
to be associated with various problems. Powles et al 23 showed that after allogeneic BMT, GM-CSF-treated Identification of patients at risk early enough would permit prompt initiation of rescue measures such as patients tended to have higher bilirubin, urea, and creatinine values, and lower platelets than placebo-treated patients. commencement/substitution of growth factor with or without a second infusion of hematopoietic stem cells before
Atkinson et al 27 found an increased incidence of grade II-IV acute GVHD among GM-CSF (molgramostim) recipithe occurrence of significant organ dysfunction or establishment of a severe infection. While it is logical and attractive ents compared with historical control patients who received no growth factors. While yeast-derived GM-CSF to think that this would have beneficial impact on early 
Table 5
Factors inflencing the probability of death/second infusion (graft failure requiring reinfusion of allogeneic or autologous marrow within 2 months of transplantation, or death due to infection, hemorrhage or graft failure within 3 months of transplantation) in multivariate analysis 
GVHD
T cell No T cell 1.9 (1.2-5.9 0.009 Figure 2 The effect of the total leukocyte count on day 16 after bone prophylaxis depletion depletion 3.4) marrow transplantation on the probability of death/second infusion. trial in this group of patients (total leukocyte count р0.2 × 10 9 /l) may also have a real chance of showing a beneficial impact of growth factors on survival and resource utilization. Giving growth factors only to patients who are (sargramostim) was found to be well-tolerated by recipients of allografts from unrelated donors in a phase I/II study in seriously ill or have already developed life-threatening infections would also curtail the use of these drugs, but Seattle, 28 a double-blind, placebo-controlled study of sargramostim at the same center in patients undergoing unremay have little impact on survival because the clinical condition of some of the patients may already have deteriolated donor transplants showed a trend towards increased non-relapse mortality and poorer 100-day survival in cytorated irreversibly. The use of blood-derived stem cells is associated with kine-treated patients. 29 Similarly, Schriber et al 30 found significant early mortality (45%) in G-CSF-treated recipients faster engraftment than marrow, especially if the day 11 dose of methotrexate is not administered. 31 In this setting, of allografts from unrelated donors, but not in recipients of sibling allografts. the decision to start growth factors may be made even earlier depending upon the leukocyte counts. Initiating growth factors only in patients whose leukocyte counts are low 12 days after transplantation, irrespec-
HLA-identical siblings, no T cell depletion
The use of the absolute neutrophil count may be more
